• XtalPi submitted a U.S. FDA IND application for KQTD-126, a gut-restricted pan-TRK inhibitor for chronic intestinal pain.
• Program targets pain linked to IBS and IBD, aiming to limit systemic exposure and reduce neurological side effects.
• Preclinical data showed IC50 below 1 nM with a gut-to-blood exposure ratio above 1,000:1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609242030PR_NEWS_USPR_____CN56775) on September 25, 2026, and is solely responsible for the information contained therein.